Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer - A pilot study

Neoplasia

Volumn 10, Issue 9, 2008, Pages 949-953

  El Sheikh, Soha Salama ^a   Romanska, Hanna M ^b   Abel, Paul ^c   Domin, Jan ^c   Lalani, El Nasir ^d  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; GONADORELIN DERIVATIVE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN EXPRESSION; SCANNING ELECTRON MICROSCOPY;

EID: 50949117490     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08582     Document Type: Article

References (19)

1. Gronberg H (2003). Prostate cancer epidemiology. Lancet 361, 859-864.
2. Auclerc G, Antoine EC, Cajfinger F, Brunet-Pommeyrol A, Agazia C, and Khayat D (2000). Management of advanced prostate cancer. Oncologist 5, 36-44.
3. De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI, Isaacs WB, and Nelson WG (2004). Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 91, 459-477.
4. Feldman BJ and Feldman D (2001). The development of androgen-independent prostate cancer. Nat Rev Cancer 1, 34-45.
5. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, and Sellers WR (1999). Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59, 4291-4296.
6. El Sheikh SS, Domin J, Abel P, Stamp G, and Lalani E (2003). Androgenindependent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalk. Neoplasia 5, 99-109.
7. Nan B, Snabboon T, Unni E, Yuan J, Whang YE, and Marcelli M (2003). The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity. J Mol Endocrinol 31, 169-183.
8. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, and Hung MC (2000). HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60, 6841-6845.
9. Lin HK, Hu YC, Yang L, Altuwaijri S, Chen YT, Kang HY, and Chang C (2003). Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem 278, 50902-50907.
10. Wu Z, Conaway M, Gioeli D, Weber MJ, and Theodorescu D (2006). Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells. Prostate 66, 1114-1123.
11. Hsu SM, Raine L, and Fanger H (1981). The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. Am J Clin Pathol 75, 816-821.
12. Torres J, Navarro S, Rogla I, Ripoll F, Lluch A, Garcia-Conde J, Llombart-Bosch A, Cervera J, and Pulido R (2001). Heterogeneous lack of expression of the tumour suppressor PTEN protein in human neoplastic tissues. Eur J Cancer 37, 114-121.
13. Schmitz M, Grignard G, Margue C, Dippel W Capesius C, Mossong J, Nathan M, Giacchi S, Scheiden R and Kieffer N (2007). Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer 120, 1284-1292.
14. Bonkhoff H, Stein U, and Remberger K (1994). The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 24, 114-118.
15. Li P, Nicosia SV, and Bai W (2001). Antagonism between PTEN/MMAC1/ TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells. J Biol Chem 276, 20444-20450.
16. Lin HK, Hu YC, Lee DK, and Chang C (2004). Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol Endocrinol 18, 2409-2423.
17. Baron S, Manin M, Beaudoin C, Leotoing L, Communal Y, Veyssiere G, and Morel L (2004). Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells. J Biol Chem 279, 14579-14586.
18. Li P, Lee H, Guo S, Unterman TG, Jenster G, and Bai W (2003). AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR Mol Cell Biol 23, 104-118.
19. Hu MC, Lee DF, Xia W Golfman LS, Ou-Yang F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, et al. (2004). IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117, 225-237.